6月23日 - ** 制药商Exelixis EXEL.O的股价盘前上涨23.8%至49.97美元
** EXEL周日在 (link)，称其实验性口服疗法zanzalintinib与罗氏ROG.S的Tecentriq联合使用，在一项晚期研究中提高了一种结直肠癌患者的生存率。
** 根据美国疾病预防控制中心（CDC）的数据，结直肠癌发生在结肠内壁，是第三大常见癌症
** 男性比女性更容易罹患这种癌症
** 截至上一交易日收盘，EXEL 股价累计上涨 21.23
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.